Articles
Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial.
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine.
The COVID-19 pandemic has had a profound impact on healthcare, especially in the management of patients with cancer, who are often not seeking healthcare in the same way as before the pandemic.
This section provides a brief overview of new cancer drugs and new indications
approved by the FDA between June 30, 2021, and July 26, 2021.
The process of clinical trials underwent a dramatic transformation amid the COVID-19 pandemic, according to Heidi D. Finnes, PharmD, BCOP, FHOPA, RPh, Senior Manager, Pharmacy Cancer Research, Mayo Clinic, Rochester, MN.
Breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, appears to be an effective alternative to surgery for women aged >60 years with low-risk, early-stage breast cancer, according to findings from the ICE3 trial.
Gastrointestinal (GI) malignancies account for 26% of the global cancer incidence and 35% of all cancer-related deaths.
The addition of the PI3K inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial.
The July issue of The Oncology Pharmacist (TOP) contains important information for today’s oncology pharmacist, including highlights from several presentations made during the 2021 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference and other key oncology meetings.
Neutropenia is characterized by low levels of neutrophils, the white blood cells that fight infections. In general, the condition is defined as an absolute neutrophil count (ANC) <1500/μL. There are several factors that can contribute to the development of neutropenia, including idiopathic and congenital etiologies, as well as some cancers, such as leukemia, myeloma, and lymphoma. However, one of the most common causes of neutropenia is the use of chemotherapy. The following provides a brief look at some of the key statistics regarding this condition.